Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Acq. announced
Director departure
CC transcript
ACHIEVE LIFE SCIENCES, INC. (ACHV) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update Company to host conference call tomorrow, Tuesday, August 15, 2023, at 8:30 AM EDT SEATTLE, Wash and VANCOUVER, British Columbia, August 14, 2023 — Achieve Life Sciences, Inc. , a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced second quarter 2023 financial results and provided an update on the cytisinicline development program. Recent Highlights • Publication of Phase 3 ORCA-2 trial results in the Journal of the American Medical Association • Reported statistically significant smoking cessation benefit for cytisinicline in the confirmatory Phase 3 ORCA-..."
06/09/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Third Amended and Restated Certificate of Incorporation, filed June 8, 2023"
06/02/2023 SC 13G/A Contrarian Alpha, LP reports a 9.7% stake in Achieve Life Sciences, Inc.
05/25/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/25/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: ". IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. 31",
"Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering SEATTLE, Wash. and VANCOUVER, British Columbia, May 25, 2023 -- Achieve Life Sciences, Inc. , a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 3,000,000 shares of common stock at a price of $5.50 per share in a registered direct offering. The aggregate gross proceeds from this offering are expected to be approximately $16.5 million, prior to deducting placement agent fees and estimated offering expenses. The Company intends to use the proceeds from the o..."
05/23/2023 8-K Investor presentation
Docs: "References 1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017. 2 U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014. 3 Cornelius ME, Loretan CG, Jamal A, et al. Tobacco Product Use Among Adults – United States, 2021. MMWR Morb Mortal Wkly Rep 2023;72:475–483. 4Park Lee E, Ren C, Cooper M, Cornelius M, Jamal A, Cullen KA. Tobacco Product Use Among Middle and High School Students – United States, 2022. Morbidity and Mortality Weekly Report, 2022; 71:45.",
"2 3 4 5 6 7 8 9 10 11 12 16 20 24"
05/17/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "2023 CONTINGENT CONVERTIBLE DEBT AGREEMENT THIS 2023 CONTINGENT CONVERTIBLE DEBT AGREEMENT is dated as of the Effective Date among SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY , in its capacity as administrative agent and collateral agent , SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY, as a lender, SVB Innovation Credit Fund VIII, L.P., a Delaware limited partnership , as a lender, INNOVATION CREDIT FUND VIII-A, L.P., a Delaware limited partnership , as a lender , and and the borrower listed on Schedule I hereto . WHEREAS, each of the Borrower, Innovation and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company , as lender and as agent thereunder, have heretofore entered into that certain 2021 Contingent Convertible Debt...",
"RECITALS WHEREAS, the Company and the Lenders are parties to that certain 2023 Contingent Convertible Debt Agreement of even date herewith, as amended or otherwise modified or supplemented and in effect from time to time ; and WHEREAS, Company and the Lenders desire to provide for certain rights of registration under the Securities Act of 1933, as amended with respect to the Conversion Shares . NOW, THEREFORE, in consideration of the promises, covenants and conditions set forth herein, the parties hereto hereby agree as follows: 1. Registration Rights. 1.1 Definitions. Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the Loan Agreement. As used in this Agreement, the following terms shall have the meanings set forth below: “Affiliate” ..."
05/16/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Consolidated Statements of Loss Three months ended March 31, 2023 2022 Operating expenses: Research and development 5,534 4,388 General and administrative 3,044 2,838 Total operating expenses 8,578 7,226 Loss from operations Other income Net loss $ $ Basic and diluted net loss per share $ $ Weighted average number of basic and diluted common shares 17,917,769 9,458,745 Consolidated Balance Sheets March 31, December 31, 2023 2022 Assets: Cash and cash equivalents $ 16,514 $ 24,771 Prepaid expenses and other current assets 1,710 2,559 Other assets and restricted cash 68 123 Right-of-use assets 109 66 License agreement 1,363 1,418 Goodwill 1,034 1,034 Total assets $ 20,798 $ 29,971 Liabilities and stockholders' equity: Accounts payable and accrued liabilities $ 3,872 $ 5,470 Current portion..."
04/28/2023 ARS Form ARS - Annual Report to Security Holders:
04/28/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/18/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
04/18/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/30/2023 8-K Quarterly results
03/23/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment to the Cooperation Agreement, by and among Achieve Life Sciences, Inc., Dialectic Capital Management, LP and the other parties set forth on the signature pages thereto"
03/23/2023 SC 13D/A DIALECTIC CAPITAL MANAGEMENT, LP reports a 19.8% stake in ACHIEVE LIFE SCIENCES, INC.
03/16/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/16/2023 8-K Quarterly results
Docs: "Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update Company to host conference call March 16, 2023, at 4:30 PM EST"
03/06/2023 SC 13D/A DIALECTIC CAPITAL MANAGEMENT, LP reports a 19.8% stake in ACHIEVE LIFE SCIENCES, INC.
03/06/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Cooperation Agreement, by and among Achieve Life Sciences, Inc., Dialectic Capital Management, LP and the other parties set forth on the signature pages thereto"
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/20/2023 SC 13D DIALECTIC CAPITAL MANAGEMENT, LP reports a 19.8% stake in ACHIEVE LIFE SCIENCES, INC.
01/12/2023 424B7 Form 424B7 - Prospectus [Rule 424(b)(7)]:
01/12/2023 EFFECT Form EFFECT - Notice of Effectiveness:
01/03/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
12/30/2022 DEL AM Form DEL AM - Delaying amendment:
12/29/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
12/07/2022 D/A Form D/A - Notice of Exempt Offering of Securities: [Amend]
11/28/2022 D Form D - Notice of Exempt Offering of Securities:
11/28/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy